Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgo biloba is a botanical extract derived from the leaves of the *Ginkgo biloba* tree, one of the oldest living tree species. It is widely utilized as a herbal medicine or dietary supplement for the treatment of cognitive impairment, various forms of dementia (including Alzheimer's and vascular dementia), and peripheral vascular disorders such as intermittent claudication. The extract is typically standardized to contain specific concentrations of active constituents, primarily flavonoid glycosides (e.g., quercetin, kaempferol) and terpene lactones (ginkgolides A, B, C, and bilobalide). Its pharmacological profile includes potent antioxidant activity, antagonism of platelet-activating factor (PAF) receptors, and improvement of blood rheology through vasodilation and reduced blood viscosity. While marketed as a traditional medicine by companies like Ergon Pharmaceuticals in Bangladesh, it has been extensively studied in clinical trials globally and is regulated as a pharmaceutical product in several European countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgo biloba.